Patent application EP19382105A (EP), filed 2019-02-15
Publication number: EP3696192A1
Title: THERAPEUTIC TARGET AND MONOCLONAL ANTIBODIES AGAINST IT FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER´S DISEASE
Abstract: The invention provides a therapeutic target for the screening of drugs for the treatment of Alzheimer's disease (AD), as well as neutralizing monoclonal antibodies against said target and their use for the treatment of AD. The invention also refers to a kit comprising the antibodies and to anin vitromethod for the diagnosis of AD in which preferably the antibodies or the kit comprising them are used.
IPC codes: A61P  25/    28            A I
C07K  16/    18            A I
Claims: number: 1
text: Use of the Sfrp1 gene, the SFRP1 mRNA or the SFRP1 protein as a therapeutic target for designing and/or screening molecules, compounds, compositions or drugs useful for the treatment and/or prevention of Alzheimer's Disease.
number: 2
text: A monoclonal antibody that specifically binds the Secreted Frizzled Related Protein 1 (SFRP1) protein, wherein the light chain of the variable region of said monoclonal antibody comprises the amino acid sequence of SEQ ID NO: 1 and the heavy chain of the variable region of said monoclonal antibody comprises the amino acid sequence of SEQ ID NO: 2.
number: 3
text: The monoclonal antibody according to claim 2, wherein said antibody is conjugated with a detection system and/or is immobilized in a support.
number: 4
text: A kit for the diagnosis of Alzheimer's Disease that comprises the monoclonal antibody according to any of claims 2 or 3.
number: 5
text: The kit according to claim 4, that further comprises a second monoclonal antibody that specifically binds the SFRP1 protein, wherein the heavy chain of the variable region of said second monoclonal antibody comprises the amino acid sequence of SEQ ID NO: 3.
number: 6
text: The kit according to claim 5, wherein the second monoclonal antibody is conjugated with a detection system and/or is immobilized in a support.
number: 7
text: A pharmaceutical composition comprising an inhibitor of the SFRP1 protein or Sfrp1 gene biological function.
number: 8
text: The pharmaceutical composition according to claim 7, wherein the inhibitor is the monoclonal antibody according to any of claims 2 or 3.
number: 9
text: The pharmaceutical composition according to claim 8, which further comprises a second monoclonal antibody that specifically binds the SFRP1 protein, wherein the heavy chain of the variable region of said second monoclonal antibody comprises the amino acid sequence of SEQ ID NO: 3.
number: 10
text: An inhibitor of the SFRP1 protein or Sfrp1 gene biological function for use as a medicament.
number: 11
text: An inhibitor of the SFRP1 protein or Sfrp1 gene biological function for use in the treatment and/or prevention of Alzheimer's Disease.
number: 12
text: An inhibitor of the SFRP1 protein or Sfrp1 gene biological function for use according to any of claims 10 or 11, wherein the inhibitor is the monoclonal antibody according to any of claims 2 or 3.
number: 13
text: Use of the monoclonal antibody according to any of claims 2 or 3 or the kit according to any one of claims 4 to 6 in the in vitro diagnosis of Alzheimer's Disease.
number: 14
text: Use according to claim 13, wherein the diagnosis of Alzheimer's Disease is performed by immunoassay, preferably by ELISA.
number: 15
text: A method for the in vitro diagnosis of Alzheimer's Disease in a subject that comprises the following steps:
number: 16
text: The method according to claim 15, wherein steps (a) to (c) are performed by immunoassay, preferably by ELISA.
number: 17
text: The method according to any of claims 15 or 16, wherein the isolated biological sample is a brain sample, preferably a brain cortex sample, or cerebrospinal fluid.
Office action: search_report, dated 2020-08-19
Rejection reasons: novelty_epc_54
Prior art cited: ref_id: WO2017211827A1
ref_type: patent
severity: background
ref_id: - SEVIGNY, J. ET AL., NATURE, vol. 537, no. 7618, 2016, pages 50 - 56
ref_type: npl
severity: background
ref_id: - VAN DYCK, BIOL. PSYCHIATRY, vol. 83, 2018, pages 311 - 319
ref_type: npl
severity: background
ref_id: - GOLDE, T.E. ET AL., NEURON, vol. 69, 2011, pages 203 - 213
ref_type: npl
severity: background
ref_id: - FOWLER, S.W. ET AL., J NEUROSCI, vol. 34, 2014, pages 7871 - 7885
ref_type: npl
severity: background
ref_id: - SEVIGNY, J. ET AL., NATURE, vol. 537, 2016, pages 50 - 56
ref_type: npl
severity: background
ref_id: - BOVOLENTA, P. ET AL., JOURNAL OF CELL SCIENCE, vol. 121, 2008, pages 737 - 746
ref_type: npl
severity: background
ref_id: - MATSUDA ET AL., BREAST CANCER RES., vol. 11, 2009, pages R32
ref_type: npl
severity: background
ref_id: - BERNEMANN ET AL., MOLECULAR CANCER, vol. 13, 2014, pages 174
ref_type: npl
severity: background
ref_id: - "UniProtKB", Database accession no. Q8N474
ref_type: npl
severity: background
ref_id: WO0119855A2
ref_type: patent
severity: background
ref_id: WO2006124887A1
ref_type: patent
severity: background
ref_id: US2004265995A1
ref_type: patent
severity: background
ref_id: WO2012136871A1
ref_type: patent
severity: background
ref_id: WO02055547A2
ref_type: patent
severity: background
ref_id: - WARRIER SUDHA ET AL: "sFRP-mediated Wnt sequestration as a potential therapeutic target for Alzheimer's disease", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, PERGAMON, GB, vol. 75, 7 April 2016 (2016-04-07), pages 104 - 111, XP029537306, ISSN: 1357-2725, DOI: 10.1016/J.BIOCEL.2016.04.002
ref_type: npl
severity: background
ref_id: - ESTEVE PILAR ET AL: "Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis", NATURE NEUROSCIENCE, NATURE AMERICA, INC, US, vol. 22, no. 8, 15 July 2019 (2019-07-15), pages 1258 - 1268, XP036843812, ISSN: 1097-6256, [retrieved on 20190715], DOI: 10.1038/S41593-019-0432-1
ref_type: npl
severity: background
ref_id: WO0119855
ref_type: patent
severity: novelty_destroying
ref_id: WO02055547
ref_type: patent
severity: background
ref_id: US2004265995
ref_type: patent
severity: novelty_destroying
ref_id: WO2006124887
ref_type: patent
severity: novelty_destroying
ref_id: WO2012136871
ref_type: patent
severity: background
ref_id: - WARRIER SUDHA ET AL, "sFRP-mediated Wnt sequestration as a potential therapeutic target for Alzheimer's disease", INTERNATIONAL JOURNAL OF BIOCHEMISTRY AND CELL BIOLOGY, PERGAMON, GB, (20160407), vol. 75, doi:10.1016/J.BIOCEL.2016.04.002, ISSN 1357-2725, pages 104 - 111, XP029537306 [A] 1-17 * the whole document *
ref_type: npl
severity: background
ref_id: - ESTEVE PILAR ET AL, "Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis", NATURE NEUROSCIENCE, NATURE AMERICA, INC, US, vol. 22, no. 8, doi:10.1038/S41593-019-0432-1, ISSN 1097-6256, (20190715), pages 1258 - 1268, (20190715), XP036843812 [T] * the whole document *
ref_type: npl
severity: background
Final disposition: pending (2020-08-19)